R&D Spotlight:
AI in Drug Discovery
AI in Drug Discovery
SPONSORED BY
Discover the latest advances in artificial intelligence across the drug discovery process.
Explore how AI and machine learning are being applied to drug design, target identification and validation, and increasingly integrated into discovery workflows to accelerate candidate generation and improve decision-making. This focused online showcase brings together industry experts to examine practical applications of AI-driven discovery platforms, computational approaches and emerging strategies for integrating AI into modern drug discovery.
- Accelerate Drug Design – Explore how AI and computational approaches can support the design, optimisation and prioritisation of promising drug candidates
- Advance Target Identification – Gain insights into AI-driven approaches for identifying and validating therapeutic targets and generating new biological insights
- Practical AI Insights – Hear from experts through industry presentations, a solution spotlight, extended Q&A and panel discussion focused on real-world applications and challenges in AI-driven drug discovery
VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:
- AI & Machine Learning
- Drug Discovery
- Computational Drug Design
- Target Identification & Validation
- Computational Chemistry
- Cheminformatics
- Computational Biology
- Data Science
- Medicinal Chemistry
- Drug Development
60-Minute Agenda
Industry Presentation
Industry Presentation
Solution Provider Presentation
Panel Discussion
End of Technology Showcase
About 10x Genomics
10x Genomics builds technologies that turn biology into answers, giving researchers the resolution to see how diseases develop and respond to treatment.
Its Chromium Single Cell platform delivers single cell multiomics across thousands of samples and billions of cells, even from FFPE, while its spatial portfolio spans Atera In Situ, Xenium In Situ, and Visium Spatial for whole transcriptome insight at subcellular resolution.
Newer additions like Flex Apex and Atera push sample access and throughput further still, profiling FFPE and fixed whole blood and running up to 800 whole transcriptome samples per year. This work powers breakthroughs across pharma, oncology, immunology, and AI cell models, and has been cited in over 10,000 publications by scientists advancing their research worldwide.
